0000000000595152

AUTHOR

S Onali

showing 2 related works from this author

Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer

2017

The debate about the best approach to select patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT) is still ongoing. This study aims to identify the best variables allowing to discriminate between "high-" and "low-benefit" patients. To do so, the concept of intention-to-treat (ITT) survival benefit of LT has been created. Data of 2,103 adult HCC patients consecutively enlisted during the period 1987-2015 were analyzed. Three rigorous statistical steps were used in order to create the ITT survival benefit of LT: the development of an ITT LT and a non-LT survival model, and the individual prediction of the ITT survival benefit of LT defined as the difference between…

Malemedicine.medical_specialtySettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatment030230 surgeryMilan criteriaLiver transplantation03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver Transplantation; HepatologyHumansRisk factorHepatology; hepatocellular cancer; liver transplantationCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver TransplantationSurvival analysisRetrospective StudiesIntention-to-treat analysisHepatologybusiness.industryCarcinomaLiver NeoplasmsRetrospective cohort studyHepatocellularHepatologyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationSettore MED/18Europehepatocellular cancer030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Adalimumab in active ulcerative colitis: A “real-life” observational study

2013

Abstract Background and aims The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results Eighty-eight patients we…

musculoskeletal diseasesAdultMaleAdalimumab “Real-life” study Ulcerative colitismedicine.medical_specialtymedicine.medical_treatmentIBDAnti-Inflammatory AgentsAdalimumab; “Real-life” study; Ulcerative colitisAntibodies Monoclonal HumanizedPlaceboCohort StudiesYoung AdultRefractoryAdrenal Cortex HormonesInternal medicineAdalimumabmedicineHumansskin and connective tissue diseases“Real-life” studyRetrospective StudiesColectomySettore MED/12 - GastroenterologiaHepatologybusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyAdalimumabmedicine.diseaseUlcerative colitishumanitiesInfliximabSurgeryDiscontinuationTreatment OutcomeUlcerative colitisCohortColitis UlcerativeDrug Therapy CombinationFemalebusinessmedicine.drug
researchProduct